Biohit Oyj (OHEL:BIOBV) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:BIOBV Biohit Oyj OHEL:BIOBV
83 GF Score
Price €2.44
GF Value €2.64
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Biohit Oyj FFO?

FFO (Funds from operations) only applies to REITs.

OHEL:BIOBV
83GF Score
Biohit Oyj OHEL:BIOBV
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biohit Oyj (OHEL:BIOBV) Overvalued in 2026?

Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued. The current stock price of €2.44 is trading 7.6% below its estimated GF Value™ of €2.64. GuruFocus considers Biohit Oyj to be Fairly Valued.

Key valuation signals for OHEL:BIOBV:

  • FFO:
  • GF Value™: €2.64 vs. price of €2.44 (7.6% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the OHEL:BIOBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biohit Oyj Business Description

Other Exchanges 0DRP:UK
Address Laippatie 1, Helsinki, FIN, 00880
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
83GF Score

Get the complete analysis for OHEL:BIOBV

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price
€2.64
GF Value